載入中
NASDAQHealthcareMedical - Pharmaceuticals
最新資料
US$27.38
−US$0.64 · -2.28%
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
前收盤價
US$27.38
−US$0.64 · -2.28%
盤中時間採用ET。市場資料可能有所延遲。
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
日內區間
目前US$27.38
52週區間
目前US$27.38
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
買進
估值
87
深度低估
情緒
47
多空交錯
風險
37
中等風險
動能
71
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
Liquidia Corporation operates as a biopharmaceutical enterprise, concentrating on the development, production, and market introduction of various treatments aimed at fulfilling critical patient requirements throughout the United States. A key asset in its developmental portfolio is YUTREPIA, an innovative inhaled dry powder version of treprostinil, intended for managing pulmonary arterial hypertension. Beyond its pipeline, the company also distributes a generic treprostinil injection within the U.S. market. Founded in 2004, Liquidia Corporation's main office is located in Morrisville, North Carolina.
日內區間
目前US$27.38
52週區間
目前US$27.38
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 1.58億 USD | 1399.6萬 USD | 1748.8萬 USD | 1593.5萬 USD | 1285.3萬 USD |
| 銷貨成本 | 1324.2萬 USD | 587.9萬 USD | 288.8萬 USD | 285.9萬 USD | 302.3萬 USD |
| 毛利 | 1.45億 USD | 811.7萬 USD | 1460萬 USD | 1307.6萬 USD | 983萬 USD |
| 研究與開發 | 3927.6萬 USD | 4784.2萬 USD | 4324.2萬 USD | 1943.5萬 USD | 2051.7萬 USD |
| 銷售、一般及管理費用 | 1.57億 USD | 8156.9萬 USD | 4474.2萬 USD | 3241.1萬 USD | 2311萬 USD |
| 營業費用 | 1.96億 USD | 1.29億 USD | 8798.4萬 USD | 5184.6萬 USD | 4362.7萬 USD |
| 利息收入 | 662.4萬 USD | 765.4萬 USD | 346.6萬 USD | 109萬 USD | 3.3萬 USD |
| 利息支出 | 2417.2萬 USD | 1248.6萬 USD | 627.3萬 USD | 233.8萬 USD | 76.2萬 USD |
| 折舊和攤銷 | 152.8萬 USD | 219.7萬 USD | 217.8萬 USD | 364.7萬 USD | 561.2萬 USD |
| 營業利益 | −5137.6萬 USD | −1.21億 USD | −7338.4萬 USD | −3877萬 USD | −3379.7萬 USD |
| 淨利 | −6892.4萬 USD | −1.3億 USD | −7850.2萬 USD | −4101.5萬 USD | −3457.9萬 USD |
公司資料更新於 2026年10月12日。
近期已公布業績
近期已公布業績
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$83.20
上漲空間 203.87%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI1.54億0.01%2.3兆 USD0.03%US$381.94+0.63%
iShares Core S&P Small-Cap ETFIJR1.24億0.12%1031.91億 USD0.06%US$137.55+0.17%
Vanguard Extended Market ETFVXF5564.44萬0.06%954億 USD0.05%US$235+0.80%
iShares Russell 2000 ETFIWM5202.54萬0.07%787.4億 USD0.19%US$278.94+0.49%
Vanguard Russell 2000 ETFVTWO2765.28萬0.15%180億 USD0.06%US$112.66+0.50%
Invesco S&P SmallCap Momentum ETFXSMO2390.99萬0.83%28.69億 USD0.35%US$81.75+0.57%
State Street SPDR Portfolio S&P 600 Small Cap ETFSPSM1921.2萬0.12%158.4億 USD0.03%US$53.45+0.17%
iShares Russell 2000 Growth ETFIWO1826.55萬0.13%139.17億 USD0.24%US$356.78+0.94%Vanguard Morningstar Total Stock Market ETFVTIiShares Core S&P Small-Cap ETFIJRVanguard Extended Market ETFVXFiShares Russell 2000 ETFIWMVanguard Russell 2000 ETFVTWOInvesco S&P SmallCap Momentum ETFXSMOState Street SPDR Portfolio S&P 600 Small Cap ETFSPSMiShares Russell 2000 Growth ETFIWOAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
